By VINCENT MAO, INVESTOR'S BUSINESS DAILY
Posted 09:02 AM ET
Santarus (SNTS) jumped 9% in pre-market trade after blowing away views late Tuesday. The drug maker's earnings and sales bolted 210% and 89% in the latest quarters. Profit has grown by triple digits or better in the latest five quarters. Santarus cleared a 24 buy point from a six-week base July 9, but was quickly sent back to its 50-day line.